Do β1-selective β-blockers increase the risk of arrhythmic events compared to nonselective β-blockers in symptomatic children with CPVT?
Nonselective β-blockers, specifically nadolol, should be preferred over β1-selective β-blockers for treating symptomatic children with CPVT to minimize arrhythmic events.
β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.
Peltenburg et al. (Tue,) studied this question.